On 7 September 2026, TENNOR THERAP-B (06872.HK) reported positive Phase IIa proof-of-concept data for rifaquizalone (TNP-2092) in prosthetic joint infection. Based on these data, a multicenter Phase IIb trial has been approved by the NMPA and recently initiated.
On 7 September 2026, CSTONE PHARMA-B (02616.HK) announced that its shares have been added to the Stock Connect eligible list, effective 7 September 2026. CEO Dr. Yang Jianxin stated that the inclusion is expected to broaden the investor base and enhance liquidity. Core asset CS2009 trispecific antibody is advancing in global Phase I/II, with the first global Phase III registrational trial expected to start before end-2026.
On 6 September 2026, FOSUN PHARMA (02196.HK) announced that its subsidiary Fosun Pharma Singapore sold 9.897 million shares (6.00%) of India's Gland Pharma on 4 September 2026 for approximately USD 294 million, at a 2.72% discount to the previous closing price. Post-transaction, the group's stake falls to approximately 45.76% while it remains the controlling shareholder; proceeds are designated for R&D investment, share buybacks and debt repayment, with settlement expected on 7 September 2026 India time.
On 6 September 2026, PICC GROUP (01339.HK) approved the nomination of Ms. Yang Dongning as a candidate for executive director of the fifth session of the Board.
On 6 September 2026, KEYMED BIO-B (02162.HK) announced that Dr. Wang Minchuan has resigned as a non-executive director, effective 4 September 2026, to focus on other commitments, confirming no disagreement with the Board and no matters requiring shareholder or exchange attention.
On 7 September 2026, KINTOR PHARMA-B (09939.HK) announced the completion of the long-term safety trial of KT-939, a novel tyrosinase inhibitor, on 4 September 2026, with no skin adverse reactions observed among 114 subjects after 52 weeks of continuous use of 0.2% KT-939.
On 7 September 2026, RIVERINE CHINA (01417.HK) announced that its public float stood at approximately 23.85%, below the 25% minimum required by the Listing Rules, after 8,218,000 shares (approximately 2.03% of issued share capital) held by the share award scheme trustee were excluded from the public float. The company is considering options including trustee share sales and/or a new share issuance to the public, and expects to restore the public float within 6 months.
On 7 September 2026, CLOVER BIO-B (02197.HK) reported positive Phase II data for respiratory combination vaccine candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) among 420 elderly subjects in Australia.
On 7 September 2026, WANGUO GOLD GP (03939.HK) announced a subscription of USD 103,834,600 in the JPMorgan Mansart Overnight Fund on 4 September 2026, constituting a discloseable transaction.
During the week (31 August to 4 September), Hong Kong equities diverged: the HSI rose 0.26%, the Hang Seng TECH Index fell 0.77% and the HSCEI rose 0.76%, with net southbound inflows of about HK$ 7.363 billion for the full week. The HSI quarterly review took effect, adding Hua Hong Grace and Weichai Power, while Iluvatar CoreX joined the HSTECH; Goldman Sachs expects USD 870 million of passive inflows into tech hardware and semiconductors. The MSCI China Index review took effect, adding Z.AI and Kingboard Holdings. Baidu completed its dual primary listing and could join Stock Connect as early as 7 September. The AI application sector led gains on OpenAI's GPT-6 Astra release, with PHANCY up nearly 15%; HUTCHMED's major licensing deal with GSK triggered a breakout in innovative drug names. Semiconductors diverged sharply, with Hua Hong Grace tumbling 8.43% despite its HSI inclusion.
On 6 September 2026, Anton Oilfield Services Group (03337.HK) announced that it obtained approval from the Iraqi Ministry of Oil and signed a long-term cooperation agreement with the State Oil Marketing Company (SOMO) on the same day, securing the crude oil sales qualification and the right to lift crude from the Iraqi national oil company's self-operated oilfields, becoming Iraq's designated crude oil export sales partner and the only independent Chinese oil and gas energy company in the Iraqi market with simultaneous qualifications in oilfield services, resource development and crude sales.
On 6 September 2026, Fosun International Limited (00656.HK) announced that Fosun Pharma Industrial Pte. Ltd., its indirect subsidiary, disposed of 9,897,000 shares of Gland Pharma Limited (approximately 6.00% of its total issued shares) on 4 September 2026 (India time) by way of block trades and centralised auction, for a total consideration of approximately INR 27.996 billion (about USD 294 million); the Group's interest fell to 45.76% from 51.76%, and the Target remains a subsidiary whose financial statements will continue to be consolidated, with no gain or loss expected.
On 6 September 2026, Beijing Zhongke WengeAI Science and Technology Co., Ltd. (01956.HK) announced that its H shares have been included in the eligible securities list for Stock Connect with effect from 7 September 2026, after which eligible Mainland Chinese investors can trade the H shares directly through the Stock Connect mechanism.
On 6 September 2026, ZHIHU-W (02390.HK) announced that Beijing Zhizhe Tansuo Technology Co., Ltd., its wholly-owned subsidiary, agreed to subscribe for limited partnership interests in Tianjin Lisi Xingshen Equity Investment Partnership (Limited Partnership) with a capital contribution of RMB 1,500,000,000; the Fund will primarily invest in early- and mid-stage unlisted AI companies in the Chinese mainland, and the subscription, constituting a major transaction, is subject to shareholders' approval at an extraordinary general meeting, with a circular expected on or before 30 September 2026.
On 6 September 2026, Baige Online Digital Technology Co., Ltd. (02672.HK) reported MaaS service revenue of approximately RMB 47.4 million for the period from 1 January to 31 August 2026, up about 579.8% year on year, with service calls exceeding 7.5 million, as its AI risk-control large-model services entered scaled commercial deployment.
Hong Kong's recently listed stocks were mixed this week, with UNISOUND up 32.31% to lead the gains and MININGLAMP-W and TOPNC up over 23%; SHEIN-W and MECH-MIND ROBOTICS fell over 21% in their debut week, while CF PHARMTECH dropped 24.19%, the worst performer. AUX ELECTRIC fell only 5.05% on the week after releasing 1.301 billion shares from lock-up. MINIMAX-W's average daily turnover of HKD 7.168 billion overtook Z.AI for the top spot. DEEPZERO extended its cumulative gain to 1,599% to keep leading, while ZG GROUP-W was the most deeply discounted at 93.05% below its IPO price. Only three stocks face lock-up expiries next week, all of small size.
